Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Entelos has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, under which Entelos will use its 'virtual patients' approach as a platform to discover and evaluate potential new therapies for treating type-2 diabetes.
Subscribe to our email newsletter
James Karis, president and CEO of Entelos, said: “The deal reinforces Entelos’s stated strategy to enable proprietary drug development, particularly in chronic disease areas where multiple drugs, treatment choices, and large differences between patients make it difficult for health-care providers to select the best treatments.”